RSS-Feed abonnieren
DOI: 10.1055/a-2104-1614
Observation of a Possible Successful Treatment of DEPDC5-Related Epilepsy with mTOR Inhibitor
Funding The study was supported by the Medical School of University of Pécs, “ÁOK-KA” Research Program; KA-2021-13.
Abstract
The mechanistic target of the rapamycin signaling pathway serves as a central regulator of cell metabolism, growth, proliferation, and survival. In its regulation, the GTPase-activating protein activity toward Rags1 complex has an inhibitory effect. Mutations in genes encoding this complex protein are among the most common abnormalities in focal epilepsies. Within these mutations, the mutations affecting the DEPDC5 gene have been associated with different autosomal dominantly inherited epilepsy types. Due to the limited data available on mTOR inhibitor therapy in nontuberous sclerosis complex epileptic patients, here we present the clinical management of a patient with intractable epilepsy, skin hypopigmentation, and a DEPDC5 variant. The patient's phenotype is compatible with a nonlesional DEPDC5-related epileptic encephalopathy. We initiated compassionate, off-label everolimus treatment as the patient's condition continuously deteriorated. Due to bilateral pneumonia occurring at the beginning of the treatment, it was temporarily discontinued, and resumed in half the dose. Follow-up examination after 18 months showed a 90% reduction in seizure frequency with moderate improvement in attention function and nutritional status. Our case report emphasizes the importance of early genetic testing in patients with epileptic encephalopathy. Clinical consequences of mammalian target of rapamycin complex 1 (mTORC1) upregulation may be amenable to tailored treatment with mTOR inhibitors. A clinical trial on an international scale would be needed to draw conclusions.
Publikationsverlauf
Eingereicht: 21. Juli 2022
Angenommen: 18. April 2023
Accepted Manuscript online:
01. Juni 2023
Artikel online veröffentlicht:
30. Juli 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Iffland II PH, Carson V, Bordey A, Crino PB. GATORopathies: the role of amino acid regulatory gene mutations in epilepsy and cortical malformations. Epilepsia 2019; 60 (11) 2163-2173
- 2 Baldassari S, Picard F, Verbeek NE. et al. The landscape of epilepsy-related GATOR1 variants. Genet Med 2019; 21 (02) 398-408
- 3 Baldassari S, Licchetta L, Tinuper P, Bisulli F, Pippucci T. GATOR1 complex: the common genetic actor in focal epilepsies. J Med Genet 2016; 53 (08) 503-510
- 4 Krueger DA, Wilfong AA, Holland-Bouley K. et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013; 74 (05) 679-687
- 5 Meng LH, Zheng XF. Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol Sin 2015; 36 (10) 1163-1169
- 6 Parker WE, Orlova KA, Parker WH. et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med 2013; 5 (182): 182ra53
- 7 Nguyen LH, Brewster AL, Clark ME. et al. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia. Epilepsia 2015; 56 (04) 636-646
- 8 Scheffer IE, Heron SE, Regan BM. et al. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol 2014; 75 (05) 782-787
- 9 Ribierre T, Deleuze C, Bacq A. et al. Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia-associated epilepsy. J Clin Invest 2018; 128 (06) 2452-2458
- 10 Crino PB, Aronica E, Baltuch G, Nathanson KL. Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology 2010; 74 (21) 1716-1723
- 11 Carmignac V, Mignot C, Blanchard E. et al. Clinical spectrum of MTOR-related hypomelanosis of Ito with neurodevelopmental abnormalities. Genet Med 2021; 23 (08) 1484-1491
- 12 von Stülpnagel C, van Baalen A, Borggraefe I. et al; NETRE Consortium. Network for therapy in rare epilepsies (NETRE): lessons from the past 15 years. Front Neurol 2021; 11: 622510
- 13 Hadouiri N, Darmency V, Guibaud L. et al. Compassionate use of everolimus for refractory epilepsy in a patient with MTOR mosaic mutation. Eur J Med Genet 2020; 63 (11) 104036